CN103462951B - Application of scopariusins in preparation of medicine treating or preventing canker sore - Google Patents
Application of scopariusins in preparation of medicine treating or preventing canker sore Download PDFInfo
- Publication number
- CN103462951B CN103462951B CN201310470463.XA CN201310470463A CN103462951B CN 103462951 B CN103462951 B CN 103462951B CN 201310470463 A CN201310470463 A CN 201310470463A CN 103462951 B CN103462951 B CN 103462951B
- Authority
- CN
- China
- Prior art keywords
- scopariusins
- canker sore
- day
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention provides the application of scopariusins in preparation of the medicine treating or preventing the canker sore. The application is disclosed for the first time. The matrix type of the scopariusins belongs to a brand new matrix type. The scopariusins has the advantages of being high in activity of treatment of the canker sore and prominent in substantive features, and makes remarkable progress in treatment of the canker sore.
Description
Technical field
The present invention relates to the novelty teabag of compound S copariusins, particularly relate to the application of Scopariusins in preparation treatment or preventing canker sore medicine.
Background technology
Recurrent oral ulceration is modal disease in diseases of oral mucosa.The first place of prevalence office diseases of oral mucosa.Sircus(1975) investigate 1587 people, prevalence is 20%.As can be seen here, oral ulcer patient is a very huge colony.The cause of disease of recurrent oral ulceration is complicated, still indefinite so far, may be relevant with the factor such as the endocrine regulation of viral infection, bacteriological infection and body, immune dysfunction.The primary treatment measure of oral ulcer comprises topical therapeutic and whole body therapeutic, and because topical therapeutic toxic and side effects is lower, the people therefore obtaining people can.Although the buccal tablets that the local that occurs in recent years uses carries, easy to use, mouthfeel and compliance better, as lysozyme buccal tablet, watermelon crystal buccal tablet, cydiodine etc., these medicines emphasize particularly on different fields in sterilization, antiinflammatory, pain relieving etc.
The compound S copariusins that the present invention relates to is one and delivers (Min Zhou in 2013, et al., Scopariusins, A New Class of ent-Halimane Diterpenoids Isolated from Isodonscoparius, and Biomimetic Synthesis of Scopariusin A and Isoscoparin N.OrganicLetters, 2013, noval chemical compound 15(2): 314 – 317.), this compound has brand-new framework types, research finds not have significant inhibitory action (Min Zhou to melanoma cell etc., et al., Scopariusins, A NewClass of ent-Halimane Diterpenoids Isolated from Isodon scoparius, and BiomimeticSynthesis of Scopariusin A and Isoscoparin N.Organic Letters, 2013, 15(2): 314 – 317.), the purposes of the Scopariusins that the present invention relates in preparation treatment or preventing canker sore medicine belongs to first public.
Summary of the invention
The object of the invention is to not find that it has the present situation of the report for the treatment of or preventing canker sore according in existing Scopariusins research, provide the application of Scopariusins in preparation treatment or preventing canker sore medicine.
Described compound S copariusins structure is as shown in formula I:
The purposes of the Scopariusins that the present invention relates in preparation treatment or preventing canker sore medicine belongs to first public, because framework types belongs to brand-new framework types, and its treatment or preventing canker sore active strong, possess outstanding substantive distinguishing features, to be used for the treatment of or preventing canker sore obviously has significant progress simultaneously.
Detailed description of the invention
The preparation method of compound S copariusins involved in the present invention is see document (Min Zhou, et al., Scopariusins, A New Class of ent-Halimane Diterpenoids Isolated from Isodonscoparius, and Biomimetic Synthesis of Scopariusin A and Isoscoparin N.OrganicLetters, 2013,15(2): 314 – 317.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound S copariusins tablet involved in the present invention:
Get 5 g of compound Scopariusins and add 195 grams, dextrin, mixing, Conventional compression makes 1000.
Embodiment 2: the preparation of compound S copariusins capsule involved in the present invention:
Get 5 g of compound Scopariusins and add starch 195 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
The experimental study of test example 1:Scopariusins anti-oral ulcer
1, test objective: manufacture Oral ulcer model with phenol, gives the Scopariusins of Oral ulcer model rat certain number of times every day, and whether observe Scopariusins has the effect reducing ulcer.
2, test medicine and reagent
Cydiodine (Beijing Sihuan Medicine Science and Technology Co., Ltd); Phenol
Animal: Wistar rat, male, body weight 240 ~ 280g, Nanjing Medical University's Experimental Animal Center.
3, test method
Get rat 50, male, body weight 240 ~ 280g, 10% chloral hydrate anesthesia, dosage: 0.35ml/100g, is flat on rats with left bicker by plastic dropper (internal diameter: the 3mm) lower end of 90% phenol cotton balls after anesthesia and is about on the cheek film at 1mm place, calcination 30min, is namely shown in the white infringement of this place about 3mm.Divide into groups immediately after 24 hours, often organize 10, divide 5 groups, i.e. model group (adjuvant 4 times/day, not drug containing); Scopariusins high dose group (4 times/day, 0.5mg/ time); Dosage (4 times/day, 0.1mg/ time) in Scopariusins; Scopariusins low dose group (4 times/day, 0.02mg/ time); Positive controls: cydiodine group (4 times/day, 0.5mg/ time).Scopariusins and cydiodine buccal tablet pulverize before use, administration is degree of being with flap coverage.Successive administration 5 days, after the front and each administration of administration, next day observes ulcer area size (diameter in ulcer) and ulcer healing situation (being considered as healing without macroscopic ulcer), and first administration is recorded as 1,2,3,4,5,6 day respectively to last administration.Ulcer area size t checks, and ulcer healing rate X2 checks.4, result of the test
Ulcer area compares (table 1): Scopariusins high dose group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; Cydiodine group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; In Scopariusins, dosage group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; Scopariusins low dose group compares with model group, within the 5th day, plays off-test from administration, and corresponding every day compares significant difference; In Scopariusins, dosage group compares with cydiodine group, within the 1st day, plays off-test from administration, and corresponding every day compares significant difference.
Table 1 is on the impact of rat ulcer area
Note: compare with model group, * p<0.05, * p<0.01.
Healing rate (table 2): model group and Scopariusins low dose group play off-test on the 1st day from administration, and ulcer does not heal; And Scopariusins high dose group was from administration the 4th day, just there is ulcer healing, to off-test, reach 90%; Cydiodine group, from administration the 4th day, has ulcer healing, to off-test, reaches 60%; In Scopariusins, dosage group was from administration the 5th day, had ulcer healing, to off-test, reached 40%.
Table 2 is on the impact of rat ulcer healing time
Note: compare with model group, * p<0.05, * p<0.01.
5, conclusion
Scopariusins has the effect obviously promoting oral ulcer healing.
Claims (1)
- The application of 1.Scopariusins in preparation treatment or preventing canker sore medicine, described compound S copariusins structure is as shown in formula I:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310470463.XA CN103462951B (en) | 2013-10-10 | 2013-10-10 | Application of scopariusins in preparation of medicine treating or preventing canker sore |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310470463.XA CN103462951B (en) | 2013-10-10 | 2013-10-10 | Application of scopariusins in preparation of medicine treating or preventing canker sore |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103462951A CN103462951A (en) | 2013-12-25 |
| CN103462951B true CN103462951B (en) | 2015-04-01 |
Family
ID=49788149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310470463.XA Expired - Fee Related CN103462951B (en) | 2013-10-10 | 2013-10-10 | Application of scopariusins in preparation of medicine treating or preventing canker sore |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103462951B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107669782A (en) * | 2017-10-04 | 2018-02-09 | 南京正宽医药科技有限公司 | A kind of Chinese medicinal granule product for reducing blood glucose and preparation method thereof |
-
2013
- 2013-10-10 CN CN201310470463.XA patent/CN103462951B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103462951A (en) | 2013-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN103585147B (en) | Application of Nitrosporeusines A in preparation of oral ulcer treatment or prevention medicines | |
| CN103599104B (en) | Application of Caesanines D in drug for treating or preventing dental ulcer | |
| CN103505464B (en) | The application of Phyllanthoid A in preparation treatment or preventing canker sore medicine | |
| CN103479624B (en) | Application of Racemosins A in preparation of oral ulcer treatment or prevention medicines | |
| CN103638005B (en) | The application of Hippolachnin A in treatment or preventing canker sore medicine | |
| CN103356653B (en) | The application of Chukrasone A in preparation treatment or preventing canker sore medicine | |
| CN107501435A (en) | The extracting method of pachymaran and its application | |
| CN106344555A (en) | Application of Fistulains B in drugs for dental ulcer prevention or treatment | |
| CN105287543A (en) | Application of strynuxlines B to prepare medicines treating or preventing oral ulcer | |
| CN105412109A (en) | Application of Biscarpamontamine B in preparing drugs for treating or preventing dental ulcers | |
| CN105434428A (en) | Applications of Volvalerelactones B in preparing drugs used for treating or preventing dental ulcer | |
| CN105147676A (en) | Medicine for preventing or treating dental ulcer | |
| CN105232531A (en) | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers | |
| CN102988382B (en) | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer | |
| CN106491621A (en) | Friedolanostanes is preparing treatment or the application in preventing canker sore medicine | |
| CN103263423A (en) | Application of myriberine A in preparation of medicaments for treating or preventing canker sores | |
| CN102872056B (en) | Application of Gypensapogenin A to preparing drugs for treating or preventing canker sores | |
| CN102872060B (en) | Application of Gypensapogenin B to preparing drugs for treating or preventing canker sores | |
| CN103462998A (en) | Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer | |
| CN103961654B (en) | A kind of White staphylococcus sheet and preparation method thereof | |
| CN106265638A (en) | Linderolide H application in preparation treatment or preventing canker sore medicine | |
| CN103127077A (en) | Application of Aphanamixoid A to dental ulcer treatment or prevention medicine | |
| CN103381160A (en) | Applications of Chukrasone B in medicines used for curing or preventing oral ulcer | |
| CN103315994A (en) | Application of Aphanamgrandiol A in preparation of medicine used for preventing or treating oral ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ZIBO QIDINGLI PATENT INFORMATION CONSULTATION CO., Free format text: FORMER OWNER: GAO WEI Effective date: 20150304 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xu Liming Inventor after: Sun Yuping Inventor after: Song Gang Inventor after: Gao Wei Inventor before: Gao Wei |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: GAO WEI TO: XU LIMING SUN YUPING SONG GANG GAO WEI Free format text: CORRECT: ADDRESS; FROM: 255400 ZIBO, SHANDONG PROVINCE TO: 255086 ZIBO, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150304 Address after: Industrial Park No. 87 Yu Bridge 255086 Shandong province Zibo high tech Zone Wanjie Road Room 301 Applicant after: Zibo Qidingli Patent Information Consulting Co., Ltd. Address before: Linzi Luo Jia Cun 255400 area in Shandong city of Zibo province Zhu town No. 18 Applicant before: Gao Wei |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 225300 Jiangsu City, Gaogang District, city road, No. 58, No. Patentee after: Zibo Qidingli Patent Information Consulting Co., Ltd. Address before: Industrial Park No. 87 Yu Bridge 255086 Shandong province Zibo high tech Zone Wanjie Road Room 301 Patentee before: Zibo Qidingli Patent Information Consulting Co., Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Meng Yanhua Inventor after: Liang Ruji Inventor before: Xu Liming Inventor before: Sun Yuping Inventor before: Song Gang Inventor before: Gao Wei |
|
| COR | Change of bibliographic data | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170228 Address after: 253419 Shandong County, Ningjin Zhen Bao Zhen Street Village, No. 101 Patentee after: Meng Yanhua Patentee after: Liang Ruji Address before: 225300 Jiangsu City, Gaogang District, city road, No. 58, No. Patentee before: Zibo Qidingli Patent Information Consulting Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150401 Termination date: 20171010 |